Genetic blood test could spare many pregnancies from unnecessary monitoring
NCT ID NCT07715214
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests whether a blood test using next-generation sequencing (NGS) can accurately determine the blood type of an unborn baby. In about 1% of pregnancies, the mother's immune system produces antibodies that can attack the baby's red blood cells, potentially causing anemia or other serious complications. Current methods to assess risk are imperfect, leading to unnecessary monitoring in about 30% of cases. By analyzing fetal DNA from a maternal blood sample, researchers aim to reliably identify which babies are truly at risk and which are not, improving care and reducing anxiety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NGS analysis for fetal red cell blood type in maternal plasma
- What this could lead to
- If successful, this approach could replace current imperfect methods, allowing doctors to accurately identify which fetuses are truly at risk and avoid unnecessary monitoring for those who are not.
- What could go wrong
- This is an implementation study focused on accuracy and logistics, not a treatment trial. The technology may not prove reliable enough in all cases, and broader use would require further validation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HDFN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.